A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy and in combination with pembrolizumab, in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer (R/M HNSCC) Meeting Abstract
| Authors: | Colevas, A. D.; Chung, C. H.; Adkins, D.; Rodriguez, C. P.; Park, J. C.; Gibson, M. K.; Sukari, A.; Worden, F. P.; Johnson, F. M.; Saba, N. F.; Burtness, B.; Julian, R. A.; Bauman, J. E.; Jotte, R. M.; Seiwert, T. Y.; Dunn, L.; Chaney, M. F.; Margossian, S.; Levisetti, M.; Pai, S. I. |
| Abstract Title: | A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy and in combination with pembrolizumab, in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer (R/M HNSCC) |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557401469 |
| PROVIDER: | wos |
| DOI: | :10.1200/JCO.2024.42.16_suppl.6004 |
| Notes: | Meeting Abstract: 6004-- Source: Wos |
